Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Hepatitis C pills drive surge in U.S. drug costs: report

Highly effective but expensive new pills to treat hepatitis C drove a 13.1 percent increase U.S. prescription drug spending in 2014, the fastest rate of increase in more than a decade, according to Express Scripts.

Published
12 March 2015
From
Reuters
Re-infection due to ongoing risk probably the cause of HCV recurrence after SVR

Rates of hepatitis C virus (HCV) reoccurrence after successful therapy differ markedly between risk groups, according to the results of a meta-analysis presented at the recent Conference on

Published
11 March 2015
By
Michael Carter
Sofosbuvir/ledipasvir raises some antiretroviral levels in HIV/HCV coinfected people

People with HIV and hepatitis C virus (HCV) co-infection who take sofosbuvir/ledipasvir (Harvoni) to treat hepatitis C along with boosted protease inhibitor antiretroviral regimens may experience changes

Published
10 March 2015
By
Liz Highleyman
Here Is Why Gilead Sciences, Inc. Is Still Doing Better Than AbbVie Inc

Based on the prescription data released by Symphony Health, the latest Bloomberg Intelligence (BI) analysis suggests that 95% of hepatitis C patients in the US are being administered with Gilead’s drugs, Harvoni and Sovaldi. On the other hand, AbbVie’s competing drug, Viekira Pak is only covering the remaining 4%.

Published
10 March 2015
From
Bidness
$10 Copy of Gilead Blockbuster Sovaldi Appears in Bangladesh

Incepta Pharmaceuticals Ltd. doesn’t have a license from Gilead and its version was launched last month, said Managing Director Abdul Muktadir. The company also aims to sell the drug overseas, including to parts of Southeast Asia and Africa.

Published
09 March 2015
From
Bloomberg
EECA CAB positions in regards to Janssen, BMS, Gilead and ViiV policy

EECA CAB (Community Advisory Board in Eastern Europe and Central Asia) has published its positions in regards to Janssen, BMS, ViiV and Gilead policy. The positions were developed on the results of the meetings with the companies during last year.

Published
09 March 2015
From
EATG
NIH-led study to assess community-based hepatitis C treatment in Washington, D.C.

Officials from NIH and the city of Washington, D.C., launched a clinical trial to examine whether primary care physicians and other health care providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection. The trial, which will involve 600 adult D.C. residents infected with HCV alone or co-infected with HCV and HIV, also will examine the long-term effects of the treatment.

Published
09 March 2015
From
EurekAlert
Natco Pharma ties up with Gilead on hepatitis C drugs

Natco, a mid-sized player in India's crowded pharmaceutical industry, is the latest generic drugmaker to team up with Gilead on Sovaldi, having previously attempted to block the U.S. firm from getting a patent for the breakthrough drug in India in the hope of producing a cheaper version on its own. In September, Gilead announced similar licensing deals with seven other generic drugmakers.

Published
04 March 2015
From
Reuters
HCV Drugs Costly but Cure Might Not Be

Despite controversy over the cost of new hepatitis C (HCV) medications, they appear to be cheaper on a per-cure basis than earlier drugs, a researcher said here.

Published
04 March 2015
From
MedPage Today
Gilead's Harvoni gains NICE yes - but won't face funding delay

Gilead's next generation hepatitis C pill Harvoni is set to be backed by NICE - and this time NHS England won't be delaying its funding as it has done with the firm's other hep C drug Sovaldi.

Published
03 March 2015
From
PM Live

Filter by country